We have been asked if the Company has dropped the CEP program from our list of clinical studies as it wasn’t mentioned in the latest Appendix 4C.
The answer is, no, we haven’t. But it is not a priority.
We have a busy clinical program using NOX66 in combination with radiotherapy, and we anticipate the NOX66 DARRT program as our route to market. So, that is where we need to focus our efforts and funds. The Appendix 4C simply narrative reflected that focus.
Despite its lower priority, as previously stated, an Australian-based Advisory Board is being assembled to discuss the options for a Phase 2 CEP study in relation to preferred tumour type and NOX66-chemotherapy combination.
At this stage, a Phase 2 CEP study is viewed as a means of generating data that will be used in the marketing of NOX66 to support its extended use as a chemo-enhancer once it is approved for use as a radio-enhancer.